Study of the Safety and Immunogenicity of NasoVAX Extension
NCT03760549
·
clinicaltrials.gov ↗
COMPLETED
Status
8
Enrollment
INDUSTRY
Sponsor class
Conditions
Influenza
Interventions
DRUG:
Subjects were administered NasoVAX high dose
Sponsor
Altimmune, Inc.